retatrutide type 2 diabetes phase 2 results 2024 ada More data on dropped today at the conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the More Phase 3 data from

Monthly costs without coverage run approximately $300 to $400 CAD for Ozempic depending on pharmacy and dose

I think that once Mounjaro is approved for weight loss at the end of 2023 this trend will gain steam in a significant way, which would likely reflect in Q2-Q3 2024 earnings for PHG, RMD etc

Keep a simple log if you need to track which site you used last

Paralytic ileus happens when the ileum becomes blocked, preventing food, liquids, and gas from moving through the digestive tract into the large intestine

Many of you also want to know, "are GLP-1 patches FDA approved?" This is a critical question

GLP-1 medications affect people differently